Onali, Sebastiano
 Distribuzione geografica
Continente #
EU - Europa 201
NA - Nord America 182
AS - Asia 98
SA - Sud America 23
AF - Africa 1
Totale 505
Nazione #
US - Stati Uniti d'America 179
IT - Italia 57
SE - Svezia 48
SG - Singapore 42
CN - Cina 27
DE - Germania 25
BR - Brasile 22
FR - Francia 19
IE - Irlanda 12
ID - Indonesia 9
FI - Finlandia 8
AT - Austria 6
GB - Regno Unito 6
HK - Hong Kong 6
IN - India 4
PL - Polonia 4
RU - Federazione Russa 4
BE - Belgio 3
CZ - Repubblica Ceca 3
KR - Corea 3
CA - Canada 2
UZ - Uzbekistan 2
AL - Albania 1
AR - Argentina 1
CI - Costa d'Avorio 1
EE - Estonia 1
HU - Ungheria 1
IR - Iran 1
JP - Giappone 1
LT - Lituania 1
MX - Messico 1
NL - Olanda 1
NP - Nepal 1
SA - Arabia Saudita 1
TR - Turchia 1
UA - Ucraina 1
Totale 505
Città #
Chandler 50
Singapore 36
Rome 19
Ashburn 15
Milan 14
New York 14
Dublin 12
Jakarta 9
Los Angeles 9
Cagliari 7
Helsinki 7
Frankfurt am Main 6
Marseille 6
Portsmouth 6
Princeton 6
Boston 5
Düsseldorf 5
Vienna 5
Guasila 4
Hong Kong 4
Nuremberg 4
Brussels 3
Hefei 3
Hyderabad 3
Seoul 3
Shenyang 3
Wroclaw 3
Belo Horizonte 2
Bremen 2
Brno 2
Carapicuíba 2
Falkenstein 2
Moscow 2
Munich 2
Paris 2
Pavia 2
Portocannone 2
Samarkand 2
San Mateo 2
Seattle 2
Stockholm 2
São Paulo 2
Taiyuan 2
Abidjan 1
Baotou 1
Beijing 1
Bom Jesus do Itabapoana 1
Boydton 1
Brasília 1
Brdo 1
Cachoeira Grande 1
Castellammare del Golfo 1
Charlotte 1
Corigliano d'Otranto 1
Denver 1
Divinópolis 1
Dourados 1
Duncan 1
Grajaú 1
Guangzhou 1
Hanover 1
Houston 1
Ingeniero Jacobacci 1
Jequié 1
Kashan 1
Krimpen Aan Den Ijssel 1
Kyiv 1
Lappeenranta 1
Laranjal Paulista 1
Leawood 1
Miami 1
Mumbai 1
Nobres 1
North Charleston 1
Ottawa 1
Petrolina 1
Picos 1
Porto Alegre 1
Ribeira do Pombal 1
Richmond 1
Riyadh 1
Roteiro 1
Roubaix 1
Sacramento 1
San Francisco 1
Sopron 1
Taranto 1
The Dalles 1
Tirana 1
Tokyo 1
Toronto 1
Ubá 1
Varginha 1
Wan Chai 1
Warsaw 1
Washington 1
Wilmington 1
Totale 347
Nome #
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 72
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 71
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 64
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 63
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 58
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 56
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 49
Combined Salivary Proteome Profiling and Machine Learning Analysis Provides Insight into Molecular Signature for Autoimmune Liver Diseases Classification 35
Top-Down Proteomics Detection of Potential Salivary Biomarkers for Autoimmune Liver Diseases Classification 34
PragmaticTrial Design to Compare Real-world Effectiveness of DifferentTreatments for Inflammatory Bowel Diseases:The PRACTICE-IBD European Consensus 17
Totale 519
Categoria #
all - tutte 3.196
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.196


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202242 0 0 0 0 0 0 0 0 0 0 22 20
2022/2023152 20 21 10 20 9 15 8 14 26 1 5 3
2023/2024111 3 27 2 8 9 20 7 8 1 4 9 13
2024/2025214 4 3 23 6 19 15 31 9 20 37 44 3
Totale 519